Sphingosine-1-phosphate as a potential target for the treatment of myocardial infarction

Circulation Journal

Volumn 78, Issue 4, 2014, Pages 795-802

  Waeber, Christian ^a   Walther, Thomas ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Acute myocardial infarction; Coronary artery disease; Fibrosis; Hypertrophy; Lipids

Indexed keywords

2 AMINO 2 (3 OCTYLPHENYLCARBAMOYL)ETHYL PHOSPHATE; 4 (2,6 DICHLORO 4 PYRIDINYL) 1 (1,3 DIMETHYL 4 ISOPROPYL 1H PYRAZOLO[3,4 B]PYRIDIN 6 YL)SEMICARBAZIDE; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; ALBUMIN; CYCLOOXYGENASE 2; FINGOLIMOD; HIGH DENSITY LIPOPROTEIN; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; W146;

BLOOD LEVEL; CELL PROTECTION; DRUG TARGETING; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; METABOLISM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; LIPOPROTEINS, HDL; LYSOPHOSPHOLIPIDS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84897863825     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-14-0178     Document Type: Review

References (90)

1. Spiegel S, Milstien S. Sphingosine-1-phosphate: Signaling inside and out. FEBS Lett 2000; 476: 55-57.
2. Hla T, Maciag T. An abundant transcript induced in differentiating human endothelial cells encodes a polypeptide with structural similarities to G-protein-coupled receptors. J Biol Chem 1990; 265: 9308-9313.
3. Chun J, Goetzl EJ, Hla T, Igarashi Y, Lynch KR, Moolenaar W, et al. International Union of Pharmacology XXXIV: Lysophospholipid receptor nomenclature. Pharmacol Rev 2002; 54: 265-269.
4. Waeber C, Blondeau N, Salomone S. Vascular sphingosine-1-phos-phate S1P1 and S1P3 receptors. Drug News Perspect 2004; 17: 365-382.
5. Waeber C. Sphingosine 1-phosphate (S1P) signaling and the vascu-lature. In: Chun J, Hla T, Spiegel S, Moolenaar W, editors. Lysophos-pholipid receptors: Signaling and biochemistry. New York: Wiley, 2013; 313-347.
6. Levkau B. Cardiovascular effects of sphingosine-1-phosphate (S1P). Handb Exp Pharmacol 2013: 147-170.
7. Van Brocklyn JR, Williams JB. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxida-tive stress and the seesaw of cell survival and death. Comp Biochem Physiol B Biochem Mol Biol 2012; 163: 26-36.
8. Venkataraman K, Lee YM, Michaud J, Thangada S, Ai Y, Bonkovsky HL, et al. Vascular endothelium as a contributor of plasma sphingo-sine 1-phosphate. Circ Res 2008; 102: 669-676.
9. Bode C, Sensken SC, Peest U, Beutel G, Thol F, Levkau B, et al. Erythrocytes serve as a reservoir for cellular and extracellular sphin-gosine 1-phosphate. J Cell Biochem 2010; 109: 1232-1243.
10. Hanel P, Andreani P, Graler MH. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007; 21: 1202-1209.
11. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: A decade of progress. Biochim Biophys Acta 2013; 1831: 203-212.
12. Wendler CC, Rivkees SA. Sphingosine-1-phosphate inhibits cell migration and endothelial to mesenchymal cell transformation during cardiac development. Dev Biol 2006; 291: 264-277.
13. Vessey DA, Li L, Honbo N, Karliner JS. Sphingosine 1-phosphate is an important endogenous cardioprotectant released by ischemic pre-and postconditioning. Am J Physiol Heart Circ Physiol 2009; 297: H1429-H1435.
14. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004; 92: 913-922.
15. Means CK, Xiao CY, Li Z, Zhang T, Omens JH, Ishii I, et al. Sphin-gosine 1-phosphate S1P2 and S1P3 receptor-mediated Akt activation protects against in vivo myocardial ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol 2007; 292: H2944-H2951.
16. Means CK, Brown JH. Sphingosine-1-phosphate receptor signalling in the heart. Cardiovasc Res 2009; 82: 193-200.
17. Alvarez SE, Harikumar KB, Hait NC, Allegood J, Strub GM, Kim EY, et al. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature 2010; 465: 1084-1088.
18. Strub GM, Paillard M, Liang J, Gomez L, Allegood JC, Hait NC, et al. Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. FASEB J 2011; 25: 600-612.
19. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphin-gosine-1-phosphate. Science 2009; 325: 1254-1257.
20. Nakajima N, Cavalli AL, Biral D, Glembotski CC, McDonough PM, Ho PD, et al. Expression and characterization of Edg-1 receptors in rat cardiomyocytes: Calcium deregulation in response to sphingosine 1-phosphate. Eur J Biochem 2000; 267: 5679-5686.
21. Landeen LK, Aroonsakool N, Haga JH, Hu BS, Giles WR. Sphingo-sine-1-phosphate receptor expression in cardiac fbroblasts is modulated by in vitro culture conditions. Am J Physiol Heart Circ Physiol 2007; 292: H2698-H2711.
22. Takuwa Y, Ikeda H, Okamoto Y, Takuwa N, Yoshioka K. Sphingo-sine-1-phosphate as a mediator involved in development of fbrotic diseases. Biochim Biophys Acta 2013; 1831: 185-192.
23. Kontush A, Therond P, Zerrad A, Couturier M, Nègre-Salvayre A, de Souza JA, et al. Preferential sphingosine-1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: Relevance to antiapoptotic and antioxidative activities. Ar-terioscler Thromb Vasc Biol 2007; 27: 1843-1849.
24. Aoki S, Yatomi Y, Ohta M, Osada M, Kazama F, Satoh K, et al. Sphingosine 1-phosphate-related metabolism in the blood vessel. J Biochem 2005; 138: 47-55.
25. Murata N, Sato K, Kon J, Tomura H, Yanagita M, Kuwabara A, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J 2000; 352: 809-815.
26. Nofer JR, van der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004; 113: 569-581.
27. Rye KA, Barter PJ. Predictive value of different HDL particles for the protection against or risk of coronary heart disease. Biochim Bio-phys Acta 2012; 1821: 473-480.
28. Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc Res 2009; 82: 201-211.
29. Xiong SL, Liu X, Yi GH. High-density lipoprotein induces cyclo-oxygenase-2 expression and prostaglandin I-2 release in endothelial cells through sphingosine kinase-2. Mol Cell Biochem 2014 January 3, doi:10.1007/s11010-013-1941-y.
30. Tao R, Hoover HE, Honbo N, Kalinowski M, Alano CC, Karliner JS, et al. High-density lipoprotein determines adult mouse cardio-myocyte fate after hypoxia-reoxygenation through lipoprotein-asso-ciated sphingosine 1-phosphate. Am J Physiol Heart Circ Physiol 2010; 298: H1022-H1028.
31. Theilmeier G, Schmidt C, Herrmann J, Keul P, Schafers M, Herrgott I, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the S1P3 lysophospholipid receptor. Circulation 2006; 114: 1403-1409.
32. Frias MA, James RW, Gerber-Wicht C, Lang U. Native and reconstituted HDL activate Stat3 in ventricular cardiomyocytes via ERK1/2: Role of sphingosine-1-phosphate. Cardiovasc Res 2009; 82: 313-323.
33. Frias MA, Lecour S, James RW, Pedretti S. High density lipoprotein/ sphingosine-1-phosphate-induced cardioprotection: Role of STAT3 as part of the SAFE pathway. JAKSTAT 2012; 1: 92-100.
34. Levkau B, Hermann S, Theilmeier G, van der Giet M, Chun J, Schober O, et al. High-density lipoprotein stimulates myocardial per-fusion in vivo. Circulation 2004; 110: 3355-3359.
35. Sattler KJ, Elbasan S, Keul P, Elter-Schulz M, Bode C, Graler MH, et al. Sphingosine 1-phosphate levels in plasma and HDL are altered in coronary artery disease. Basic Res Cardiol 2010; 105: 821-832.
36. Knapp M, Lisowska A, Zabielski P, Musial W, Baranowski M. Sustained decrease in plasma sphingosine-1-phosphate concentration and its accumulation in blood cells in acute myocardial infarction. Prostaglandins Other Lipid Mediat 2013; 106: 53-61.
37. Knapp M, Baranowski M, Czarnowski D, Lisowska A, Zabielski P, Gorski J, et al. Plasma sphingosine-1-phosphate concentration is reduced in patients with myocardial infarction. Med Sci Monit 2009; 15: CR490-CR493.
38. Cannavo A, Rengo G, Liccardo D, Pagano G, Zincarelli C, De Angelis MC, et al. β1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (S1PR1) reciprocal downregulation infuences cardiac hyper-trophic response and progression to heart failure: Protective role of S1PR1 cardiac gene therapy. Circulation 2013; 128: 1612-1622.
39. Egom EE, Mamas MA, Chacko S, Stringer SE, Charlton-Menys V, El-Omar M, et al. Serum sphingolipids level as a novel potential marker for early detection of human myocardial ischaemic injury. Front Physiol 2013; 4: 130.
40. Deutschman DH, Carstens JS, Klepper RL, Smith WS, Page MT, Young TR, et al. Predicting obstructive coronary artery disease with serum sphingosine-1-phosphate. Am Heart J 2003; 146: 62-68.
41. Argraves KM, Sethi AA, Gazzolo PJ, Wilkerson BA, Remaley AT, Tybjaerg-Hansen A, et al. S1P, dihydro-S1P and C24: 1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis 2011; 10: 70.
42. Gomaraschi M, Ossoli A, Favari E, Adorni MP, Sinagra G, Cattin L, et al. Inflammation impairs eNOS activation by HDL in patients with acute coronary syndrome. Cardiovasc Res 2013; 100: 36-43.
43. Tong X, Peng H, Liu D, Ji L, Niu C, Ren J, et al. High-density lipo-protein of patients with type 2 diabetes mellitus upregulates cyclo-oxgenase-2 expression and prostacyclin I-2 release in endothelial cells: Relationship with HDL-associated sphingosine-1-phosphate. Cardiovasc Diabetol 2013; 12: 27.
44. Fox TE, Bewley MC, Unrath KA, Pedersen MM, Anderson RE, Jung DY, et al. Circulating sphingolipid biomarkers in models of type 1 diabetes. J Lipid Res 2011; 52: 509-517.
45. Yeh CC, Li H, Malhotra D, Huang MC, Zhu BQ, Goetzl EJ, et al. Sphingolipid signaling and treatment during remodeling of the unin-farcted ventricular wall after myocardial infarction. Am J Physiol Heart Circ Physiol 2009; 296: H1193-H1199.
46. Vessey DA, Li L, Kelley M, Karliner JS. Combined sphingosine, S1P and ischemic postconditioning rescue the heart after protracted ischemia. Biochem Biophys Res Commun 2008; 375: 425-429.
47. Lecour S, Smith RM, Woodward B, Opie LH, Rochette L, Sack MN. Identification of a novel role for sphingolipid signaling in TNF alpha and ischemic preconditioning mediated cardioprotection. J Mol Cell Cardiol 2002; 34: 509-518.
48. Jin ZQ, Zhou HZ, Zhu P, Honbo N, Mochly-Rosen D, Messing RO, et al. Cardioprotection mediated by sphingosine-1-phosphate and gan-glioside GM-1 in wild-type and PKC epsilon knockout mouse hearts. Am J Physiol Heart Circ Physiol 2002; 282: H1970-H1977.
49. Seitz G, Boehmler AM, Kanz L, Mohle R. The role of sphingosine 1-phosphate receptors in the traffcking of hematopoietic progenitor cells. Ann NY Acad Sci 2005; 1044: 84-89.
50. Karapetyan AV, Klyachkin YM, Selim S, Sunkara M, Ziada KM, Cohen DA, et al. Bioactive lipids and cationic antimicrobial peptides as new potential regulators for traffcking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev 2013; 22: 1645-1656.
51. Karliner JS. Mechanisms of cardioprotection by lysophospholipids. J Cell Biochem 2004; 92: 1095-1103.
52. Gomez L, Paillard M, Price M, Chen Q, Teixeira G, Spiegel S, et al. A novel role for mitochondrial sphingosine-1-phosphate produced by sphingosine kinase-2 in PTP-mediated cell survival during car-dioprotection. Basic Res Cardiol 2011; 106: 1341-1353.
53. Vessey DA, Li L, Jin ZQ, Kelley M, Honbo N, Zhang J, et al. A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to isch-emic preconditioning. Oxid Med Cell Longev 2011; 2011: 961059.
54. Bandhuvula P, Honbo N, Wang GY, Jin ZQ, Fyrst H, Zhang M, et al. S1P lyase: A novel therapeutic target for ischemia-reperfusion injury of the heart. Am J Physiol Heart Circ Physiol 2011; 300: H1753-H1761.
55. Somers SJ, Frias M, Lacerda L, Opie LH, Lecour S. Interplay between SAFE and RISK pathways in sphingosine-1-phosphate-induced cardioprotection. Cardiovasc Drugs Ther 2012; 26: 227-237.
56. Egom EE, Mohamed TM, Mamas MA, Shi Y, Liu W, Chirico D, et al. Activation of Pak1/Akt/eNOS signaling following sphingosine-1-phosphate release as part of a mechanism protecting cardiomyo-cytes against ischemic cell injury. Am J Physiol Heart Circ Physiol 2011; 301: H1487-H1495.
57. Hofmann U, Burkard N, Vogt C, Thoma A, Frantz S, Ertl G, et al. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. Cardiovasc Res 2009; 83: 285-293.
58. Hofmann U, Hu K, Walter F, Burkard N, Ertl G, Bauersachs J, et al. Pharmacological pre- and post-conditioning with the sphingosine-1-phosphate receptor modulator FTY720 after myocardial ischaemia-reperfusion. Br J Pharmacol 2010; 160: 1243-1251.
59. Tsukada YT, Sanna MG, Rosen H, Gottlieb RA. S1P1-selective agonist SEW2871 exacerbates reperfusion arrhythmias. J Cardiovasc Pharmacol 2007; 50: 660-669.
60. Gellings Lowe N, Swaney JS, Moreno KM, Sabbadini RA. Sphin-gosine-1-phosphate and sphingosine kinase are critical for transforming growth factor-beta-stimulated collagen production by cardiac f-broblasts. Cardiovasc Res 2009; 82: 303-312.
61. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, et al. S1P3-mediated cardiac fbrosis in sphingosine kinase 1 trans-genic mice involves reactive oxygen species. Cardiovasc Res 2010; 85: 484-493.
62. Keller CD, Rivera Gil P, Tolle M, van der Giet M, Chun J, Radeke HH, et al. Immunomodulator FTY720 induces myofbroblast differentiation via the lysophospholipid receptor S1P3 and Smad3 signaling. Am J Pathol 2007; 170: 281-292.
63. Robert P, Tsui P, Laville MP, Livi GP, Sarau HM, Bril A, et al. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J Mol Cell Cardiol 2001; 33: 1589-1606.
64. Wei L. Lysophospholipid signaling in cardiac myocyte hypertrophy. J Mol Cell Cardiol 2004; 36: 465-468.
65. Witt W, Jannasch A, Burkhard D, Christ T, Ravens U, Brunssen C, et al. Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc Res 2012; 93: 490-497.
66. Salomone S, Yoshimura S, Reuter U, Foley M, Thomas SS, Moskowitz MA, et al. S1P3 receptors mediate the potent constriction of cerebral arteries by sphingosine-1-phosphate. Eur J Pharmacol 2003; 469: 125-134.
67. Ohmori T, Yatomi Y, Osada M, Ozaki Y. Platelet-derived sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2. J Thromb Haemost 2004; 2: 203-205.
68. Mair KM, Robinson E, Kane KA, Pyne S, Brett RR, Pyne NJ, et al. Interaction between anandamide and sphingosine-1-phosphate in mediating vasorelaxation in rat coronary artery. Br J Pharmacol 2010; 161: 176-192.
69. Hoefer J, Azam MA, Kroetsch JT, Leong-Poi H, Momen MA, Voigtlaender-Bolz J, et al. Sphingosine-1-phosphate-dependent activation of p38 MAPK maintains elevated peripheral resistance in heart failure through increased myogenic vasoconstriction. Circ Res 2010; 107: 923-933.
70. Meissner A, Yang J, Kroetsch JT, Sauve M, Dax H, Momen A, et al. Tumor necrosis factor-alpha-mediated downregulation of the cystic fbrosis transmembrane conductance regulator drives pathological sphingosine-1-phosphate signaling in a mouse model of heart failure. Circulation 2012; 125: 2739-2750.
71. Salomone S, Waeber C. Selectivity and specifcity of sphingosine-1-phosphate receptor ligands: Caveats and critical thinking in characterizing receptor-mediated effects. Front Pharmacol 2011; 2: 9.
72. Tao R, Hoover HE, Zhang J, Honbo N, Alano CC, Karliner JS. Cardiomyocyte S1P1 receptor-mediated extracellular signal-related kinase signaling and desensitization. J Cardiovasc Pharmacol 2009; 53: 486-494.
73. Guo J, MacDonell KL, Giles WR. Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pfugers Arch 1999; 438: 642-648.
74. Landeen LK, Dederko DA, Kondo CS, Hu BS, Aroonsakool N, Haga JH, et al. Mechanisms of the negative inotropic effects of sphingosine-1-phosphate on adult mouse ventricular myocytes. Am J Physiol Heart Circ Physiol 2008; 294: H736-H749.
75. Means CK, Miyamoto S, Chun J, Brown JH. S1P1 receptor localization confers selectivity for Gi-mediated cAMP and contractile responses. J Biol Chem 2008; 283: 11954-11963.
76. Zhang J, Honbo N, Goetzl EJ, Chatterjee K, Karliner JS, Gray MO. Signals from type 1 sphingosine 1-phosphate receptors enhance adult mouse cardiac myocyte survival during hypoxia. Am J Physiol Heart Circ Physiol 2007; 293: H3150-H3158.
77. Tao R, Zhang J, Vessey DA, Honbo N, Karliner JS. Deletion of the sphingosine kinase-1 gene infuences cell fate during hypoxia and glucose deprivation in adult mouse cardiomyocytes. Cardiovasc Res 2007; 74: 56-63.
78. Morel S, Frias MA, Rosker C, James RW, Rohr S, Kwak BR. The natural cardioprotective particle HDL modulates connexin43 gap junction channels. Cardiovasc Res 2012; 93: 41-49.
79. Himmel HM, Meyer Zu Heringdorf D, Graf E, Dobrev D, Kortner A, Schuler S, et al. Evidence for Edg-3 receptor-mediated activation of I(K.ACh) by sphingosine-1-phosphate in human atrial cardiomyo-cytes. Mol Pharmacol 2000; 58: 449-454.
80. + current in guinea-pig atrial myocytes by sphingosine-1-phosphate. J Physiol 1995; 489: 701-707.
81. Bunemann M, Liliom K, Brandts BK, Pott L, Tseng JL, Desiderio DM, et al. A novel membrane receptor with high affnity for lyso-sphingomyelin and sphingosine 1-phosphate in atrial myocytes. EMBO J 1996; 15: 5527-5534.
82. + currents. Cardiovasc Res 2006; 70: 88-96.
83. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transplant 2005; 5: 529-536.
84. Zhao Z, Chen Z, Zhao X, Pan F, Cai M, Wang T, et al. Sphingosine-1-phosphate promotes the differentiation of human umbilical cord mesenchymal stem cells into cardiomyocytes under the designated culturing conditions. J Biomed Sci 2011; 18: 37.
85. Walter DH, Rochwalsky U, Reinhold J, Seeger F, Aicher A, Urbich C, et al. Sphingosine-1-phosphate stimulates the functional capacity of progenitor cells by activation of the CXCR4-dependent signaling pathway via the S1P3 receptor. Arterioscler Thromb Vasc Biol 2007; 27: 275-282.
86. Kacimi R, Vessey DA, Honbo N, Karliner JS. Adult cardiac fibroblasts null for sphingosine kinase-1 exhibit growth dysregulation and an enhanced proinflammatory response. J Mol Cell Cardiol 2007; 43: 85-91.
87. Sugiyama A, Yatomi Y, Ozaki Y, Hashimoto K. Sphingosine 1-phosphate induces sinus tachycardia and coronary vasoconstriction in the canine heart. Cardiovasc Res 2000; 46: 119-125.
88. Egom EE, Ke Y, Musa H, Mohamed TM, Wang T, Cartwright E, et al. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling. J Mol Cell Cardiol 2010; 48: 406-414.
89. Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 2004; 279: 13839-13848.
90. Forrest M, Sun SY, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther 2004; 309: 758-768.